1. Pink Sheet

EU, PAHO Ink €3.8m Deal To Boost Access To Health Technologies in Latin America & Caribbean

 
• By Neena Brizmohun

Increasing the capacity for local development and production of medicines and other health technologies in Latin America and the Caribbean is among the objectives of the new deal.

drug manufacturing
Deal seeks to boost manufacturing capacity for health technologies in Latin America and the Caribbean • Source: Shutterstock

The European Commission and the Pan American Health Organization have signed a €3.8m ($4.17m) agreement that will be used to boost capacity in innovation and manufacturing of vaccines, medicines and other health technologies in Latin America and the Caribbean.

The partnership agreement was inked during the third EU-CELAC (Community of Latin American and Caribbean States) summit meeting, which took place in Brussels, Belgium, on 17-18 July

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By Vibha Sharma

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.

US FDA Rare Disease Case Studies Provide Development Models For Sponsors

 
• By Laura Helbling

Sanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices.